Stay updated on Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page.

Latest updates to the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page
- Check4 days agoChange DetectedThe screenshots show only minor UI differences with no substantive changes to core trial data (e.g., status, eligibility, or location details). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedIntroducing a government funding lapse notice and an updated software version (v3.2.0); removing the previous version tag (v3.1.0).SummaryDifference8%

- Check40 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.2%

- Check54 days agoChange DetectedUpdated to revision v3.0.2; indicates a new release with unspecified changes. The 'Back to Top' option was removed, a minor UI change.SummaryDifference0.5%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.5%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This suggests a shift towards a more generalized presentation of location data.SummaryDifference76%

Stay in the know with updates to Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page.